Table 1.
Demographic, clinical, tumor, and treatment characteristics of patients treated before (2004–2010) and after the implementation of dose constraints (2011–2016).
| Total cohort | 2004–2010 | 2011–2016 | p-value | ||
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | |||
| Gender | Female | 46 (31.7%) | 31 (36.9%) | 15 (24.6%) | 0.12 |
| Male | 99 (68.3%) | 53 (63.1%) | 46 (75.4%) | ||
| Age | < 60 years | 82 (56.6%) | 47 (56.0%) | 35 (57.4%) | 0.87 |
| ≥ 60 years | 63 (43.4%) | 37 (44.0%) | 26 (42.6%) | ||
| Compartment | Anterior | 62 (42.8%) | 38 (45.2%) | 24 (39.3%) | 0.48 |
| Posterior, medial, or groin | 83 (57.2%) | 46 (54.8%) | 37 (60.7%) | ||
| Tumor size | < 10 cm | 61 (42.1%) | 35 (41.7%) | 26 (42.6%) | 0.91 |
| ≥ 10 cm | 84 (57.9%) | 49 (58.3%) | 35 (57.4%) | ||
| Periosteal stripping | No | 113 (80.1%) | 63 (78.8%) | 50 (82.0%) | 0.64 |
| Yes | 28 (19.8%) | 17 (21.3%) | 11 (18.0%) | ||
| Radiation dose | ≤ 60 Gy | 35 (24.1%) | 15 (17.9%) | 20 (32.8%) | 0.04 |
| > 60 Gy | 110 (75.9%) | 69 (82.1%) | 41 (67.2%) | ||
| Chemotherapy | Yes | 51 (35.2%) | 30 (35.7%) | 21 (34.4%) | 0.87 |
| No | 94 (64.8%) | 54 (64.3%) | 40 (65.6%) |